CAMX icon

Cambiar Aggressive Value ETF
CAMX

31.19 USD
-0.01
0.03%
At close Feb 25, 4:00 PM EST
1 day
-0.03%
5 days
-0.89%
1 month
0.00%
3 months
1.33%
6 months
5.55%
Year to date
6.38%
1 year
12.97%
5 years
28.94%
10 years
28.94%
0
Funds holding %
of 7,290 funds
–
Analysts bullish %

Fund manager confidence

Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)

0.55% less ownership

Funds ownership: 9.56% [Q3] → 9.01% (-0.55%) [Q4]

9% less capital invested

Capital invested by funds: $5.66M [Q3] → $5.17M (-$486K) [Q4]

11% less funds holding

Funds holding: 9 [Q3] → 8 (-1) [Q4]

100% less first-time investments, than exits

New positions opened: 0 | Existing positions closed: 1

See Fund Rankings

Research analyst outlook

We haven’t received any recent analyst ratings for CAMX.

See Analyst Rankings

Financial journalist opinion

Neutral
PRNewsWire
7 months ago
Camurus announces positive Phase 3 results from the ACROINNOVA 2 study of octreotide SC depot (CAM2029) in acromegaly patients
Treatment well tolerated with a safety profile consistent with standard-of-care (SoC) Increased biochemical response rates (IGF-1 ≤ 1xULN) vs SoC at baseline Continuous improvement of acromegaly symptom and quality of life scores vs baseline Study results reinforce previously reported interim results from ACROINNOVA 21 LUND, Sweden , July 15, 2024 /PRNewswire/ -- Camurus (NASDAQ: CAMX) (STO: CAMX) today announced positive, final, topline results from the 52-week Phase 3 open-label ACROINNOVA 2 (NCT04125836) study, which evaluated safety and efficacy of the company's once-monthly octreotide subcutaneous (SC) depot (CAM2029). The study included a total of 135 patients with acromegaly who were biochemically controlled (IGF-1≤1xULN) or uncontrolled on stable doses of standard-of-care (SoC) with first generation somatostatin ligands (SRL) at screening; of these, 81 were new to study patients and 54 were roll-over patients from 24-week randomized treatment with octreotide SC depot or placebo (ACROINNOVA 1).
Camurus announces positive Phase 3 results from the ACROINNOVA 2 study of octreotide SC depot (CAM2029) in acromegaly patients
See News Rankings
Charts implemented using Lightweight Charts™